PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) has shared an update.
PharmAla Biotech Holdings Inc. has announced an agreement with Merhavim Mental Health Centre in Israel to supply MDMA for a clinical trial on PTSD related to sexual trauma, in partnership with MAPS Israel. The trial will examine MDMA’s efficacy on recent versus aged trauma, with PharmAla receiving a full data license for the trial’s results. This partnership expands PharmAla’s presence in the psychedelics industry and could enhance their data pool, potentially influencing future regulatory and commercial efforts.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. The company aims to alleviate the global shortage of clinical-grade MDMA for trials and commercial sales, while developing novel drugs in the same class. PharmAla is unique in providing clinical-grade MDMA for patient treatments outside of trials and emphasizes regulatory compliance in the psychedelics industry.
YTD Price Performance: -3.70%
Average Trading Volume: 463,689
Technical Sentiment Consensus Rating: Sell
Learn more about MDMA stock on TipRanks’ Stock Analysis page.